N-[1-(3-amino-3-oxopropyl)-5-[benzoyl(methyl)amino]benzimidazol-2-yl]-5-phenylthiophene-2-carboxamide
C29H25N5O3S — CID 11341428
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[1-(3-amino-3-oxopropyl)-5-[benzoyl(methyl)amino]benzimidazol-2-yl]-5-phenylthiophene-2-carboxamide
N-[1-(3-amino-3-oxopropyl)-5-[benzoyl(methyl)amino]benzimidazol-2-yl]-5-phenylthiophene-2-carboxamide (PubChem CID 11341428) has the molecular formula C29H25N5O3S and a molecular weight of 523.62 g/mol. Its IUPAC name is N-[1-(3-amino-3-oxopropyl)-5-[benzoyl(methyl)amino]benzimidazol-2-yl]-5-phenylthiophene-2-carboxamide.
Molecular Properties
| Compound Name | N-[1-(3-amino-3-oxopropyl)-5-[benzoyl(methyl)amino]benzimidazol-2-yl]-5-phenylthiophene-2-carboxamide |
|---|---|
| PubChem CID | 11341428 |
| Molecular Formula | C29H25N5O3S |
| Molecular Weight | 523.62 g/mol |
| Exact Mass | 523.17 |
| IUPAC Name | N-[1-(3-amino-3-oxopropyl)-5-[benzoyl(methyl)amino]benzimidazol-2-yl]-5-phenylthiophene-2-carboxamide |
| SMILES | CN(C(=O)c1ccccc1)c1ccc2c(c1)nc(NC(=O)c1ccc(-c3ccccc3)s1)n2CCC(N)=O |
| InChI | InChI=1S/C29H25N5O3S/c1-33(28(37)20-10-6-3-7-11-20)21-12-13-23-22(18-21)31-29(34(23)17-16-26(30)35)32-27(36)25-15-14-24(38-25)19-8-4-2-5-9-19/h2-15,18H,16-17H2,1H3,(H2,30,35)(H,31,32,36) |
| InChIKey | DWICUERZWRWRJK-UHFFFAOYSA-N |
| XLogP | 5.17 |
| TPSA | 110.32 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 38 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 523.62 |
| LogP ≤ 5 | 5.17 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 11341428 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.